ライフサイエンスコーパス: increased bone mass

1 tivation of osteoclastogenesis, resulting in increased bone mass.

2 hese data, JDP2(-/-) mice were found to have increased bone mass.

3 show decreased lysosomal gene expression and increased bone mass.

4 ion, which results in decreased body fat and increased bone mass.

5 istance to PPARgamma is dominant, leading to increased bone mass.

6 As a consequence, Ciz-deficient mice develop increased bone mass.

7 overexpressing a soluble receptor for leptin increased bone mass.

8 a single allele of OF45 caused significantly increased bone mass.

9 Ablation of OF45 resulted in increased bone mass.

10 These mice showed increased bone mass.

11 R109A knockout (GPR109A(-/-)) mice exhibited increased bone mass and a diminished bone-protective res

12 Vav3-deficient mice have increased bone mass and are protected from bone loss ind

13 n of cannabinoid type 1 (CB1) receptors have increased bone mass and are protected from ovariectomy-i

14 deletion of Phd2 in chondrocytes resulted in increased bone mass and bone formation rate (normalized

15 Mice lacking RAGE had increased bone mass and bone mineral density and decreas

16 CD47(-/-) mice had increased bone mass and defective osteoclast function in

17 formation, improved bone microarchitecture, increased bone mass and enhanced mechanical properties i

18 rostin antibody and zoledronic acid combined increased bone mass and fracture resistance when compare

19 Smad3+/- mice had increased bone mass and matrix properties, suggesting th

20 signaling in mature osteoblasts resulted in increased bone mass and protection from bone loss in old

21 s PTPROt was replaced with phenylalanine had increased bone mass and reduced osteoclast activity.

22 eceptor signaling in osteocytes that exhibit increased bone mass and remodeling, recognized skeletal

23 were no effects on whole-body BMD, vitamin D increased bone mass and spinal BMD, whereas high compare

24 mBMPR1A treatment also increased bone mass and strength in mice with bone loss

25 eletal impact, female HeyL null mice display increased bone mass, and Hey2 inactivation is developmen

26 lls or in differentiated osteoblasts, showed increased bone mass as adults.

27 globally or selectively in osteoblasts have increased bone mass at maturity.

28 Despite their increased bone mass, beta3-null mice contain 3.5-fold mo

29 OA patients have increased bone mass, but no corresponding decrease in fr

30 In summary, PTH administration to CR mice increased bone mass by shifting lineage allocation towar

31 We confirmed the increased bone mass caused by inhibition of osteoclast a

32 C5aR1(-/-) and C5aR2(-/-) mice displayed an increased bone mass compared to wild-type controls due t

33 Increased bone mass could partially be rescued by bone m

34 The functional outcomes considered were increased bone mass, decreased rates of bone loss, impro

35 tion of central ERalpha signaling results in increased bone mass, demonstrating that the balance betw

36 t low oral dose of 1 (mg/kg)/day body weight increased bone mass density and volume, expression of os

37 However, a second phenotype of significantly increased bone mass developed by 2 months, which continu

38 Shn3 display adult-onset osteosclerosis with increased bone mass due to augmented osteoblast activity

39 tion of Atp6v0d2 in mice results in markedly increased bone mass due to defective osteoclasts and enh

40 We showed significantly increased bone mass in 30-d SPI-fed young rats compared

41 beta1(+)CCR5(+) neutrophil numbers in BM and increased bone mass in aged mice.

42 PTH significantly increased bone mass in all cohorts despite calorie restr

43 lower spacing between trabeculae as well as increased bone mass in both males and females compared t

44 teoblast-targeted deletion of MERTK promotes increased bone mass in healthy mice and mice with cancer

45 ation of giant, nonresorbing osteoclasts and increased bone mass in male mice and protected female mi

46 pectively, in an osteoblast-specific manner, increased bone mass in mice.

47 We propose that the increased bone mass in nestin-ERalpha(-/-) mice is media

48 osteogenesis by stromal cells in culture and increased bone mass in osteoporotic mice in vivo.

49 The increased bone mass in the Foxo-deficient mice was accou

50 inc finger protein Schnurri-3 (Shn3) display increased bone mass, in part, attributable to augmented

51 cible, global deletion of SIK2 and SIK3 show increased bone mass, increased bone formation, and, dist

52 nistration of a Piezo1 agonist to adult mice increased bone mass, mimicking the effects of mechanical

53 terized by reduced bone mass (osteoporosis), increased bone mass (osteopetrosis), or abnormalities in

54 he current study, we postulated that IGFBP-2 increased bone mass partly through the activity of its h

55 mice develop osteopetrosis characterized by increased bone mass, reduced medullary cavity space and

56 In intact tibiae, ALN increased bone mass significantly more than PTH did.

57 Increased bone mass was associated with a reduction in t

58 lous bone histomorphometry revealed that the increased bone mass was the result of increased osteobla

59 Loss of SRC-2 resulted in increased bone mass, with SRC-2 KO mice having 80% highe